SynGen, a US company that focuses on the development and commercialisation of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, has appointed David Hodl, formerly Business Development Manager at Becton Dickinson, to lead commercialisation efforts for its newly formed Cell Processing Business Unit.
Hodl brings 19 years of experience in product commercialisation and business development in the life science and medical products industry to the position. During his tenure with BD's Corporate Innovation Center, he led the commercialisation of several cell-based technologies, including BD FACS CAP, an antibody-based cell surface marker profiling platform and BD's Discovery Platform, a custom cell culture environment development service.
He also played a leading role in executing the development partnership between BD and Fate Therapeutics to access proprietary technology for developing products for expansion and differentiation of induced pluripotent stem cells.
